Bisarylimidazoly fatty acid amide hydrolase inhibitors

Details Bisarylimidazoly fatty acid amide hydrolase inhibitors Bisarylimidazoly fatty acid amide hydrolase inhibitors

2007-05-15

2007-05-15

Stockton, Laura L. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S399000, C546S275100, C548S338100, C548S341500, C548S336100

Reissue Patent

active

10883195

ABSTRACT:
The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.

REFERENCES:
patent: 5648373 (1997-07-01), Winkler et al.
Levine, “New Directions in Pain Research: Molecules to Maladies,” Neuron, vol. 20, pp. 649-654, Apr. 1998.
Pasternak, “The Central Questions in Pain Perception May Be Peripheral,” Proc. Natl. Acad. Sci., USA, vol. 95, pp. 10354-10355, Sep. 1998.
Devane, et al., “Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor,” Science, vol. 258, pp. 1946-1949, Dec. 18, 1992.
Hanus, et al., “Two New Unsatured Fatty Acid Ethanolamides in Brian That bind to the Cannabinoid Receptor,” J. Med. Chem., vol. 36, pp. 3032-3034, 1993.
Mechoulam, et al., “Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors,” Biochem. Pharmacol., vol. 50, No. 1, pp. 83-90, 1995.
Barg, et al., “Cannabinomimetic Behavioral Effects of and Adenylate Cyclase Inhibition by Two New Endogenous Anandamides,” European Journal of Pharmacology, vol. 287, pp. 145-152, 1995.
Richardson, et al., “Cannabinoids Reduce Hyperalgesia and Inflammation Via Interaction with Peripheral CB1 Receptors,” Pain, vol. 75, pp. 111-119, 1998.
Jaggar, et al., “The Anti-hyperalgesic Actions of the Cannabiniod Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain,” Pain, vol. 76, pp. 189-199, 1998.
Huang, et al., “Identification of New Class of Molecules, the Arachidonyl Amide Acids, and Characterization of One Member That Inhibits Pain,” Journal of Biological Chemistry, vol. 276, No. 46, pp. 42639-42644, 2001.
Richardson, et al., “Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependant Hyperalgesia,” Journal of Neuroscience, vol. 18, No. 1, pp. 451-457, 1998.
Calignano, et al., “Control of Pain Initiation by Endogenous Cannabinoids,” Nature, vol. 394, pp. 277-280, Jul. 16, 1998.
Meng, et al., “An Analgesia Circuit Activated by Cannabinoids,” Nature, vol. 395, pp. 381-383, Sep. 24, 1998.
Meanwell, et al., “Nonprostanoid Prostacyclin Mimetics. 3. Structural Variations of the Diphenyl Heterocycle Molety,” Journal of Medicinal Chemistry, 1992, vol. 35, pp. 3498-3512.

Affiliated with

Also associated with

Rating

Bisarylimidazoly fatty acid amide hydrolase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bisarylimidazoly fatty acid amide hydrolase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bisarylimidazoly fatty acid amide hydrolase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3756278